학술논문
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
Document Type
article
Author
Marcus Butler; Rogerio Neves; Lisa Licitra; Israel Lowy; Zeynep Eroglu; Karl Lewis; Leonel Hernandez-Aya; Axel Hauschild; Emmanuel Okoye; Siyu Li; Jean-Francois Baurain; Oliver Bechter; Ketty Peris; Aleksandar Sekulic; Alexander Stratigos; Lara Dunn; Anne Lynn Chang; Michael Migden; Kosalai Mohan; Ebony Coates; Emily Ruiz; Frank Seebach; David Weinreich; George Yancopoulos; Timothy Bowler; Matthew Fury
Source
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Subject
Language
English
ISSN
2051-1426